The autonomic reflex screen (ARS) is a composite of welldefined tests of various autonomic domains and includes quantitative sudomotor axon reflex testing (QSART), heart rate response to deep breathing (HR DB ), and Valsalva maneuver [1] [2] [3] . The components of the ARS have been well validated and control values have been previously published 4 . The ARS is a valuable tool in the evaluation and diagnosis of specific entities of autonomic dysfunction such as neurogenic orthostatic hypotension, Postural Tachycardia Syndrome and specific disorders associated with autonomic impairment such as diabetic autonomic neuropathy, amyloidosis and Multiple Systems Atrophy 5-9 . Furthermore, the ARS provides a standardized measure that correlates well with autonomic dysfunction in general 10 . However, differences in autonomic function between geographic regions can occur, and control values for a given laboratory and region are important for accurate laboratory diagnosis 3 . Furthermore, the standardized data currently available are based on measurements obtained from a single laboratory and sample population and subtle differences in methodology and technique can exist between laboratories. These factors necessitate a reevaluation of control values for the ARS for different regions.
ORIGINAL ARTICLE
The present QSART data were obtained using a gel-based vehicle for delivery of acetylcholine chloride (ACh) solely using the Q-Sweat apparatus (WR Medical Electronics Co., Stillwater, MN), which is the commercially available version of the Mayobuilt sudorometer 3, 11 . Previous studies have most commonly reported QSART data obtained from the Mayo-built sudorometer using a solution-based vehicle for delivery of ACh (10% weight/volume (w/v) ionic solution) 9, 12, 13 , with a normative database having been established using this methodology 4 . Data for QSART from the Mayo-built sudorometer using a gel-based vehicle for delivery 14, 15 , as well as QSART data using Q-Sweat in conjunction with a solutionbased vehicle for delivery of ACh 11, 16 , including a normative database in Chinese participants 17 , have also been reported. However, a normative database for Q-Sweat using a gel-based vehicle for delivery of ACh has not yet been established. Such a database is of great importance, given that Q-Sweat is the standard equipment commercially available relevant to the majority of practice in Canada 11 . The Q-Sweat data presented relied on a gel-based vehicle for delivery of ACh, which provides a more efficient test and may improve patient safety 14, 15 . The objective of the current study was to provide control values from 121 healthy individuals with respect to sweat volumes obtained at standard sites (forearm, proximal leg, distal leg and foot) using the Q-Sweat apparatus in performing QSART testing with a gel electrode method. Furthermore, we provide data on the assessment of cardiovagal parasympathetic function including HRDB and Valsalva ratio (VR). Data from the head-up tilt component of the ARS will be presented as part of a separate publication which addresses the complexities of establishing normative values for this test.
METHODS

Subjects
Subject characteristics are presented in Table 1 . Subjects included in this study ranged in age from 14-76 years. Subjects were reviewed to ensure they did not have a history of orthostatic and/or autonomic dysfunction. Preliminary evaluations were performed by a neurologist (KK) and included a neurological exam and nerve conduction studies in the lower extremity to help exclude neuropathy. Further exclusion criteria included one or more of the following: i) pregnant or lactating females, ii) the presence of any cause of autonomic failure, iii) the presence of failure of other organ systems or systemic illness that can affect autonomic function or the subject's ability to cooperate. These included dementia, pheochromocytoma, heart failure, hypertension, renal or hepatic disease, severe anemia, alcoholism, malignant neoplasms, hypothyroidism, sympathectomy, or cerebrovascular accidents, iv) concomitant therapy with anticholinergic, alpha-and beta-adrenergic antagonists, or other medication which could interfere with testing of autonomic function, v) clinically significant coronary artery disease. A total of 121 subjects met the above criteria and were included in the study. Ethical approval for the study was obtained from the local institutional ethics review board and written consent was obtained from each participant prior to study commencement.
Quantitative sudomotor axon reflex testing
Studies were completed in the Autonomic Disorders Laboratory at Western University, London, Ontario using the QSweat device (WR Medical Electronics Co., Stillwater, MN) and multi-compartmental sweat capsules 4 to perform QSART at four standard sites (forearm, proximal leg, distal leg and foot). In order to assess the integrity of the postganglionic sympathetic sudomotor axon, QSART was performed as previously described 12 . Control of room temperature and humidity were maintained (23 o C and 25-35%, respectively). Skin preparations were performed according to standard clinical protocol which involves a four-step cleaning process (acetone, alcohol, water and dry gauze) 3 . A baseline sweat response was recorded. Once baseline was established, iontophoresis was performed with a stimulus of 2 mA constant current applied for five minutes to the stimulus compartment. The iontophoresis was performed using a gel preparation of 0.55 M ACh in a 2.4% wt./v agarose gel. Sweat responses were recorded for an additional five minutes after discontinuation of the stimulus.
Heart rate response to deep breathing
We performed HRDB by measuring heart rates in a supine position using an electrocardiography (ECG) device (Model 3000 Cardiac Trigger Monitor, IVY Biomedical Systems, Inc., Branford, CT). Baseline recordings were obtained for one minute. Subjects were then asked to perform eight deep breathing cycles using visual cueing at a rate of six cycles per minute. The five highest consecutive differences in peak to trough heart rates were automatically selected by the WR TestWorks™ software and manually adjusted if necessary. The values obtained were averaged to produce an average heart rate difference 1,2 .
Valsalva ratio
The VR was evaluated by measuring heart rate response to the Valsalva maneuver produced by forced exhalation into a standard Valsalva maneuver tube (WR Medical Electronics Co., Stillwater, MN) for 15 seconds at a pressure of 40 mmHg. Beatto-beat blood pressures and heart rates were measured using the Nexfin hemodynamic monitoring system (BMEYE Cardiovascular, Amsterdam, Netherlands). If necessary, the accuracy of beat-to-beat blood pressure was verified prior to beginning the Valsalva maneuver by using a sphygmomanometer cuff and a mercury manometer over the brachial artery. The VR was calculated by comparing the maximal heart rate during Valsalva maneuver to the minimum heart rate within 30 seconds of release of Valsalva maneuver 1,2 .
Data and statistical analysis
Descriptive statistics are presented as mean ± standard deviation and percentiles (2.5th, 5th, 95th and 97.5th) where indicated. For each test, we evaluated associations with age and gender using a stepwise multiple regression analysis with an alpha level of 0.05 used to denote significance. The results of these analyses, in addition to normative percentiles, were presented graphically for select tests according to the methods outlined by O'Brien and Dyck (1995) 18 . All statistical analyses were performed using SPSS® statistical software version 19 for Windows (SPSS, Inc., Chicago, IL).
RESULTS
A total of 121 healthy subjects were included in the current study and their characteristics are presented in Table 1 .
For QSART testing, the effect of gender was significant at all four sites, and age was also significant at the distal leg and foot sites. The regression equations for each site are as follows: forearm, Y = 1.932 -0.974X; proximal leg, Y = 1.993 -0.781X; where Y is total sweat volume (mL) and X is gender (0, male; 1, female). For distal leg, Y = 2.890 -1.133X 1 -0.016X 2 ; and for foot, Y = 1.907 -0.550X 1 -0.010X 2 , where Y is total sweat volume (mL), X 1 is gender (0, male; 1, female), and X 2 is age in years. Total sweat volumes obtained during QSART stratified by gender are presented for each site ( Table 2 ). Data for males (Table 3 ) and females (Table 4) is also stratified by age group (14-25, 26-40 and 41-76 years). Data is expressed as the average sweat volume per site with the associated 2.5th, 5th and 95th percentiles also presented. It should be noted that very low sweat volumes calculated for 2.5th and 5th percentiles (e.g. 0.02 mL-0.04 mL) at select sites may have been erroneously low as a result of technical issues. Figure 1 depicts scatter plots including percentiles of QSART total sweat volumes at the foot site as a function of age for male ( Figure 1a ) and female (Figure 1b ) subjects.
Our results demonstrated that HR DB and VR varied significantly by age. As these measures were not found to vary significantly by gender, the results for males and females were combined. The relationship for HR DB is expressed by the regression equation, Y = 31.66 -0.306X, where Y is average heart rate difference (bpm), and X is age in years (Figure 2a) . The relationship for VR is expressed by the regression equation, Y = 2.269 -0.010X, where Y is Valsalva ratio, and X is age in years (Figure 2b) . Measurements of cardiovagal parasympathetic function including HR DB and VR are shown in Tables 5 and 6 , respectively. Data for HR DB and VR is stratified by age group (14-25, 26-40 and 41-76 years) and data is expressed as the mean and by percentile (2.5th, 5th, 95th and 97.5th percentiles).
DISCUSSION
ARS normative data and comparison to prior studies
The results of the present study compare favorably with the findings from a previous study of healthy control subjects by Low et al(1997) 4 . In line with the QSART results from 357 subjects acquired using the Mayo-built sudorometer and an ACh solution 4 , a significant effect of gender was found for all four testing sites, with greater sweat volumes for males than for females ( Table 2) . These results are in keeping with several previous studies that have demonstrated higher sweat volumes in males 12, 13 . Sweat volumes were approximately twice as great for males as for females at the forearm and distal leg sites.
In addition to gender, age was found to have a significant effect on QSART results at the distal leg and foot sites. As a result of the differences in sweat volume between genders, further stratification based on age was performed separately for male and female data (Tables 3, 4, Figure 1 ). However, we were generally unable to show a distinction between the lower percentiles (2.5th and 5th percentiles) when sweat volumes were separated by age and gender due to small sample size. The QSART results demonstrated a pattern of lower mean sweat Values expressed as mean ± SD. Data in parentheses indicate range. m, male; f, female. 4 , which demonstrated significant effects of age at the distal leg and foot sites (also finding a significant effect at the proximal leg site) with respect to declining mean sweat volumes. Examining the significant influence of age on HR DB for data pooled across genders, mean values of average heart rate difference beats per (bpm) were found to progressively decline with age (Table 5, Figure 2A ). This finding of a reduction in heart rate variation with age is again in line with previous study results in 376 subjects 4 , and has been similarly demonstrated in a myriad of previous studies involving healthy control subjects 13, [19] [20] [21] . There was a lack of differentiation between the 2.5th and 5th percentiles in the higher age ranges with respect to heart rate variability due to limited control subjects in these age ranges (Table 5, Figure 2A ). It is difficult to recruit subjects in these age ranges due to the increased prevalence of confounding health factors such as arrhythmia and cardiac/blood pressure medications that can affect heart rate variability. A significant effect of age was also found for VR results in the present study (Table 6 , Figure 2B ). In contrast, Low et al (1997) 4 demonstrated a significant effect for both age and gender on the VR.
Sweat onset latencies not reliable or clinically helpful versus volumes
We chose to report total sweat volume, but not response latency for the QSART portion of this study. Measured as the time to sweating onset following application of the stimulus, the latter is not typically employed as an indicator of sudomotor function, and may be influenced by levels of skin resistance 3 . Furthermore, latencies can vary significantly in the context of normal sweat volumes that show reasonable test-retest reliability obtained from control subjects, further indicating that latency is not a good measure of post ganglionic sudomotor axon integrity 22 .
Sole use of gel electrode for QSART using only the Q-Sweat apparatus
This has been the first study to report sudomotor data and establish a normative database for QSART using a gel-based vehicle for delivery of ACh in conjunction with the Q-Sweat apparatus. Establishment of this normative database for Q-Sweat is necessary, given that the system is the standard commercially available equipment for clinical and research evaluation of sudomotor function 11 . The use of a gel-based vehicle for delivery of ACh has been shown to yield comparable sudomotor results to solution-based testing with no significant differences in patient comfort (based on Mayo-built sudorometer testing) 14, 15 , and offers a number of advantages. Gel formulations avoid the common technical issue of leaking associated with the use of a solution 3, 14 , which may also improve patient safety 15 . Furthermore, the use of a gel better ensures surface area contact with the underlying skin 3, 14, 15 .
CONCLUSIONS
The current study provides normative data for use in the interpretation of the ARS to aid in the evaluation of dysautonomias. Our data focuses on commercially available equipment used in the ARS evaluation, increasing the clinical application of these data. Furthermore, our study addresses questions regarding regional variation in autonomic parameters in that our results are in keeping with already published data and relevant to the assessment of patients in Southwestern Ontario and potentially the rest of Canada. We will continue to recruit control subjects to further increase our sample size in order to better address outstanding issues with respect to normative data for the ARS with a focus on lower (< 18 years) and higher (> 65 years) age ranges and the ARS components where a significant effect for both age and gender necessitate greater sample sizes (i.e. distal leg/foot sweat volumes). 
